

1. WHO Coronavirus (COVID-19) Dashboard | WHO Coronavirus (COVID-19) Dashboard With Vaccination Data [Internet]. [diakses 9 Januari 2022]. Available from: <https://covid19.who.int/>
2. Peta Sebaran | Covid19.go.id [Internet]. [diakses pada 9 Desember 2021]. Available from: <https://covid19.go.id/peta-sebaran>
3. WEBSITE CORONA SUMBAR [Internet]. [diakses pada 28 November 2021]. Available from: <https://corona.sumbarprov.go.id/web>
4. Zhao X, Jiang Y, Zhao Y, Xi H, Liu C, Qu F, et al. Analysis of the susceptibility to COVID-19 in pregnancy and recommendations on potential drug screening. *Eur J Clin Microbiol Infect Dis*. 2020;39(7):1209–20.
5. Prevalence of COVID-19 in pregnant and postnatal women - University of Birmingham [Internet]. [diakses pada 24 Desember 2021]. Available from: <https://www.birmingham.ac.uk/research/who-collaborating-centre/pregcov/about/prevalence.aspx>
6. POGI. Rekomendasi POGI Terkait Melonjaknya Kasus Ibu Hamil dengan Covid-19 dan Perlindungan Terhadap Tenaga Kesehatan. Vol. 4247608. 2021. p. 5.
7. Farnas H, Farnas H, Sriyanti R. MODE OF DELIVERY DOES NOT CORRELATE FETAL OUTCOME IN PREGNANCY WITH COVID-19 AT DR. M. DJAMIL HOSPITAL PADANG. *Andalas Obstet Gynecol J*. 2022 Feb 19;6(1):42–9. Available from: <http://jurnalobgin.fk.unand.ac.id/index.php/JOE/article/view/269>
8. Poon LC, Yang H, Kapur A, Melamed N, Dao B, Divakar H, et al. Global interim guidance on coronavirus disease 2019 (COVID-19) during pregnancy and puerperium from FIGO and allied partners: Information for healthcare professionals. *Int J Gynecol Obstet*. 2020 Jun 1;149(3):273–86.
9. Cunningham F.G., Leveno, K.J., Bloom, S.L., Hauth J. Williams obstetrics. 25nd ed. 25nd ed. united stated: McGraw-Hill Education; 2018.
10. Chen R, Zhang S, Su S, Ye H, Shu H. Interactions Between Specific Immune Status of Pregnant Women and SARS-CoV-2 Infection. *Front Cell Infect Microbiol*. 2021 Aug 12;11:753.
11. Aziz MA et al. Rekomendasi Penanganan Infeksi Virus Corona (Covid-19) Pada Maternal (Hamil, Bersalin Dan Nifas) Revisi 2. Pokja Infeksi Saluran Reproduksi Perkumpulan Obstetri dan Ginekologi Indonesia Tahun 2020 [Internet]. 2020;3–15.
12. Vogel JP, Tendal B, Giles M, Whitehead C, Burton W, Chakraborty S, et al. Clinical care of pregnant and postpartum women with COVID-19: Living recommendations from the National COVID-19 Clinical Evidence Taskforce. *Aust New Zeal J Obstet Gynaecol*. 2020 Dec 1;60(6):840–51.

13. Yan J, Guo J, Fan C, Juan J, Yu X, Li J, et al. Coronavirus disease 2019 in pregnant women: a report based on 116 cases. *Am J Obstet Gynecol* [Internet]. 2020 Jul 1;223(1):111.e1.
14. Hantoushzadeh S, Shamshirsaz AA, Aleyasin A, Seferovic MD, Aski SK, Arian SE, et al. Maternal death due to COVID-19. *Am J Obstet Gynecol*. 2020 Jul 1 [diakses pada 2022 Feb 9];223(1):109.e1. Available from: /pmc/articles/PMC7187838/
15. Prawirohardjo sarwono. Ilmu Kebidanan. PT Bustaka sarwono prawirohardjo; 2016.
16. Prof. Dr. Ida Bagus Gde Manuaba. Pengantar Kuliah Obstetri. Penerbit Buku Kedokteran. Jakarta: EGC; 2012.
17. Yulizawati, Iryani, D., Elsinta, L., Insani, A. A., & Andriani F. Asuhan. Kebidanan Pada Kehamilan. Padang: EKA CV; 2017.
18. Putrono.W. Asuhan Keperawatan Antenatal, Intranatal, dan Bayi Baru Lahir Fisiologis dan Patologis. Yogyakarta: ANDI; 2016.
19. Chen R, Zhang S, Su S, Ye H, Shu H. Interactions Between Specific Immune Status of Pregnant Women and SARS-CoV-2 Infection. *Front Cell Infect Microbiol*. 2021;11(August):1–11.
20. Bozzano F, Dentone C, Perrone C, Di Biagio A, Fenoglio D, Parodi A, et al. Extensive activation, tissue trafficking, turnover and functional impairment of NK cells in COVID-19 patients at disease onset associates with subsequent disease severity. *PLoS Pathog*. 2021 Apr 1;17(4).
21. Dashraath P, Wong JLJ, Lim MXK, Lim LM, Li S, Biswas A, et al. Coronavirus disease 2019 (COVID-19) pandemic and pregnancy. *Am J Obstet Gynecol*. 2020 Jun 1;222(6):521–31.
22. Chen R, Lan Z, Ye J, Pang L, Liu Y, Wu W, et al. Cytokine Storm: The Primary Determinant for the Pathophysiological Evolution of COVID-19 Deterioration. *Front Immunol*. 2021 Apr 28;12.
23. Shereen MA, Khan S, Kazmi A, Bashir N, Siddique R. COVID-19 infection: Emergence, transmission, and characteristics of human coronaviruses. *J Adv Res*. 2020 Jul 1;24:91–8.
24. Zhou P, Yang X Lou, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. *Nature*. 2020 Mar 12;579(7798):270–3.
25. Liu T, Hu J, Kang M, Lin L, Zhong H, Xiao J, et al. Transmission dynamics of 2019 novel coronavirus (2019-nCoV). *bioRxiv*. 2020;
26. Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. *Cell*. 2020 Apr 16;181(2):271.

27. Gao K, Nguyen DD, Wang R, Wei GW. Machine intelligence design of 2019-nCoV drugs. *bioRxiv Prepr Serv Biol* [Internet]. 2020 [diakses pada 2022 Feb 10];
28. Ceraolo C, Giorgi FM. Genomic variance of the 2019-nCoV coronavirus. *J Med Virol*. 2020 May 1;92(5):522–8.
29. Lapostolle F, Schneider E, Vianu I, Dollet G, Roche B, Berdah J, et al. Clinical features of 1487 COVID-19 patients with outpatient management in the Greater Paris: the COVID-call study. *Intern Emerg Med*. 2020 Aug 1;15(5):813–7.
30. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet (London, England)*. 2020 Feb 15;395(10223):497–506.
31. Suresh Kumar VC, Mukherjee S, Harne PS, Subedi A, Ganapathy MK, Patthipati VS, et al. Novelty in the gut: a systematic review and meta-analysis of the gastrointestinal manifestations of COVID-19. *BMJ open Gastroenterol*. 2020 May 25;7(1).
32. Pencegahan DJ, Pengendalian Penyakit (P2P) KKR. Pedoman Kesiapsiagaan Menghadapi Infeksi Novel Coronavirus (2019- nCoV). 2020;
33. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China. *JAMA*. 2020 Mar 17;323(11):1061.
34. Infection prevention and control during health care when novel coronavirus (nCoV) infection is suspected. [diakses pada 2022 Feb 10].
35. Handayani D, Hadi DR, Isbaniah F, Burhan E, Agustin H. Corona Virus Disease 2019. *J Respirologi Indones*. 2020 Apr 30;40(2):119–29.
36. Clinical management of severe acute respiratory infection when novel coronavirus (2019-nCoV) infection is suspected: interim guidance, 28 January 2020..
37. Wan Y, Shang J, Graham R, Baric RS, Li F. Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus. *J Virol*. 2020 Mar 17;94(7).
38. Ziegler CGK, Allon SJ, Nyquist SK, Mbano IM, Miao VN, Tzouanas CN, et al. SARS-CoV-2 Receptor ACE2 Is an Interferon-Stimulated Gene in Human Airway Epithelial Cells and Is Detected in Specific Cell Subsets across Tissues. *Cell*. 2020 May 28;181(5):1016-1035.e19.
39. Kotlyar AM, Grechukhina O, Chen A, Popkhadze S, Grimshaw A, Tal O, et al. Vertical transmission of coronavirus disease 2019: a systematic review and meta-analysis. *Am J Obstet Gynecol*. 2021 Jan 1 ;224(1):35.
40. Fenizia C, Biasin M, Cetin I, Vergani P, Mileto D, Spinillo A, et al. Analysis of SARS-CoV-2 vertical transmission during pregnancy.

41. Gunawan sulistia gan. FARMAKOLOGI DAN TERAPI. edisi 6. jakarta: penerbit FKUI; 2016.
42. Katzung, B.G., Masters, S.B. dan Trevor A. Farmakologi Dasar &. Klinik, Vol.2, Edisi 12. 12th ed. Ricky Soeharsono et al, editor. jakarta: Penerbit Buku Kedokteran EGC; 2014.
43. Carl P. Weiner, Clifford Mason. DRUGS FOR PREGNANT AND LACTATING WOMEN, 3rd EDITION. 3rd ed. Philadelphia: Elsevier Inc.; 2020.
44. Sukmawati E, Sari wahyunita yulia, Sulistyoningrum I. Farmakologi Kebidanan. jakarta: trans info media; 2018.
45. Singh V, Choudhary A. Treatment With Remdesivir in Two Pregnant Patients With COVID-19 Pneumonia. *Cureus*. 2021;13(5):1–6.
46. Sisti G, Schiattarella A, Sisti A. Treatment of covid-19 in pregnancy with hydroxychloroquine and azithromycin: A case report. *Acta Biomed*. 2020;91(4):1–4.
47. Saroyo YB, Rumondang A, Febriana IS, Harzif AK, Irwinda R. Remdesivir treatment for COVID 19 in pregnant patients with moderate to severe symptoms: Serial case report. *Infect Dis Rep*. 2021;13(2):437–43.
48. Calderón JM, del Rocío del RF, Coria LP, Briones Garduño JC, Figueroa JM, Vargas Contreras MJ, et al. Nitazoxanide against COVID-19 in three explorative scenarios. *J Infect Dev Ctries*. 2020;14(9):982–6.
49. Zheng T, Guo J, He W, Wang H, Yu H, Ye H. Coronavirus disease 2019 (COVID-19) in pregnancy: 2 case reports on maternal and neonatal outcomes in Yichang city, Hubei Province, China. *Medicine (Baltimore)*. 2020;99(29):e21334.
50. Ogamba I, Chuang L, Panarelli E, Zilberman D. A case report of COVID-19 infection and management during pregnancy. *SAGE Open Med Case Reports*. 2021;9.
51. San-Juan R, Barbero P, Fernández-Ruiz M, López-Medrano F, Lizasoain M, Hernández-Jiménez P, et al. Incidence and clinical profiles of COVID-19 pneumonia in pregnant women: A single-centre cohort study from Spain. *EClinicalMedicine*. 2020 Jun 1;23:100407.
52. Tirmikçioğlu Z. Favipiravir exposure and pregnancy outcome of COVID-19 patients. *Eur J Obstet Gynecol Reprod Biol*. 2022 Jan 1;268:110–5.
53. Amirian ES, Levy JK. Current knowledge about the antivirals remdesivir (GS-5734) and GS-441524 as therapeutic options for coronaviruses. *One Heal (Amsterdam, Netherlands)*. 2020 Jun 1;9.
54. Repurposed Antiviral Drugs for Covid-19 — Interim WHO Solidarity Trial Results. *N Engl J Med*. 2021 Feb 11;384(6):497–511.

55. BPOM. Informatorium obat COVID-19 di Indonesia. BPOM RI. Jakarta: BPOM RI; 2020.
56. Brown AJ, Won JJ, Graham RL, Dinno KH, Sims AC, Feng JY, et al. Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase. *Antiviral Res.* 2019 Sep 1;169.
57. Sheahan TP, Sims AC, Leist SR, Schäfer A, Won J, Brown AJ, et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV.
58. Grein J, Ohmagari N, Shin D, Diaz G, Asperges E, Castagna A, et al. Compassionate Use of Remdesivir for Patients with Severe Covid-19. *N Engl J Med.* 2020 Jun 11;382(24):2327–36.
59. Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. Remdesivir for the Treatment of Covid-19 — Final Report. *N Engl J Med.* 2020;383(19):1813–26.
60. Dou D, Revol R, Östbye H, Wang H, Daniels R. Influenza A Virus Cell Entry, Replication, Virion Assembly and Movement. *Front Immunol.* 2018 Jul 20;9(JUL).
61. LL B, R H-D, BJ K. Goodman & Gilman's: the pharmacological basis of therapeutics. 13th ed. New York: McGraw-Hill Education; 2018.
62. Beigel JH, Manosuthi W, Beeler J, Bao Y, Hoppers M, Ruxrungtham K, et al. Effect of oral oseltamivir on virological outcomes in low-risk adults with influenza: A randomized clinical trial. *Clin Infect Dis.* 2020;70(11):2317–24.
63. Wu X, Cai Y, Huang X, Yu X, Zhao L, Wang F, et al. Co-infection with SARS-CoV-2 and Influenza A Virus in Patient with Pneumonia, China. *Emerg Infect Dis.* 2020 Jun 1;26(6):1324–6.
64. Lim J, Jeon S, Shin HY, Kim MJ, Seong YM, Lee WJ, et al. Case of the Index Patient Who Caused Tertiary Transmission of COVID-19 Infection in Korea: the Application of Lopinavir/Ritonavir for the Treatment of COVID-19 Infected Pneumonia Monitored by Quantitative RT-PCR. *J Korean Med Sci.* 2020 Feb 17;35(6).
65. Sheahan TP, Sims AC, Leist SR, Schäfer A, Won J, Brown AJ, et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. *Nat Commun.* 2020 Dec 1;11(1).
66. Hung IFN, Lung KC, Tso EYK, Liu R, Chung TWH, Chu MY, et al. Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. *Lancet.* 2020 May 30;395(10238):1695–704.

67. Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19. *N Engl J Med*. 2020;382(19):1787–99.
68. Cai Q. Experimental Treatment with Favipiravir for COVID-19 An Open-Label. *J Infect*. 2020;80(6):14–8.
69. Delang L, Abdelnabi R, Neyts J. Favipiravir as a potential countermeasure against neglected and emerging RNA viruses. *Antiviral Res*. 2018 May 1;153:85–94.
70. Dong L, Hu S, Gao J. Discovering drugs to treat coronavirus disease 2019 (COVID-19). *Drug Discov Ther*. 2020 Feb 29;14(1):58–60.
71. Rossignol J-F, Bardin MC, Fulgencio J, Mogelnicki D, Bréchet C. A randomized double-blind placebo-controlled clinical trial of nitazoxanide for treatment of mild or moderate COVID-19. *eClinicalMedicine*. 2022;45:101310.
72. Wang Z, Yang B, Li Q, Wen L, Zhang R. Clinical Features of 69 Cases With Coronavirus Disease 2019 in Wuhan, China. *Clin Infect Dis*. 2020 Aug 1;71(15):769–77.
73. Alavi Darazam I, Shokouhi S, Mardani M, Pourhoseingholi MA, Rabiei MM, Hatami F, et al. Umifenovir in hospitalized moderate to severe COVID-19 patients: A randomized clinical trial. *Int Immunopharmacol*. 2021 Oct 1;99.
74. Lansbury L, Lim B, Baskaran V, Lim WS. Co-infections in people with COVID-19: a systematic review and meta-analysis. *J Infect*. 2020;81:266–75.
75. Jin YH, Cai L, Cheng ZS, Cheng H, Deng T, Fan YP, et al. A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version). *Mil Med Res*. 2020 Feb 6;7(1):1–23.
76. Liang H, Acharya G. Novel corona virus disease (COVID-19) in pregnancy: What clinical recommendations to follow? *Acta Obstet Gynecol Scand*. 2020 Apr 1;99(4):439–42.
77. Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. *Int J Antimicrob Agents*. 2020 Jul 1;56(1):105949.
78. Chen J, Liu D, Liu L, Liu P, Xu Q, Xia L, et al. [A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19]. *Zhejiang Da Xue Xue Bao Yi Xue Ban*. 2020 May 25;49(2):215–9.
79. Huang M, Tang T, Pang P, Li M, Ma R, Lu J, et al. Treating COVID-19 with Chloroquine. *J Mol Cell Biol*. 2020;12(4):322–5.
80. Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-

nCoV) in vitro. *Cell Res* 2020 303. 2020 Feb 4;30(3):269–71.

81. Multicenter collaboration group of Department of Science and Technology of Guangdong Province and Health Commission of Guangdong Province for chloroquine in the treatment of novel coronavirus pneumonia. [Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia]. *Zhonghua Jie He He Hu Xi Za Zhi* [Internet]. 2020 Mar 12 [diakses pada 1 Februari 2022];43(3):185–8. Available from: <https://pubmed.ncbi.nlm.nih.gov/32164085/>
82. Tomazini BM, Maia IS, Cavalcanti AB, Berwanger O, Rosa RG, Veiga VC, et al. Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19: The CoDEX Randomized Clinical Trial. *JAMA*. 2020 Oct 6;324(13):1307–16.
83. Corral-Gudino L, Bahamonde A, Arnaiz-Revillas F, Gómez-Barquero J, Abadía-Otero J, García-Ibarbia C, et al. GLUCOCOVID: A controlled trial of methylprednisolone in adults hospitalized with COVID-19 pneumonia. *medRxiv*. 2020 Jun 18;2020.06.17.20133579.
84. Bikdeli B, Madhavan M V., Jimenez D, Chuich T, Dreyfus I, Driggin E, et al. COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art Review. *J Am Coll Cardiol*. 2020 Jun 16;75(23):2950–73.
85. D’Souza R, Malhamé I, Teshler L, Acharya G, Hunt BJ, McLintock C. A critical review of the pathophysiology of thrombotic complications and clinical practice recommendations for thromboprophylaxis in pregnant patients with COVID-19. *Acta Obstet Gynecol Scand*. 2020 Sep 1;99(9):1110–20.
86. Metz TD, Clifton RG, Hughes BL, Sandoval G, Saade GR, Grobman WA, et al. Disease Severity and Perinatal Outcomes of Pregnant Patients With Coronavirus Disease 2019 (COVID-19). *Obstet Gynecol*. 2021 Apr 1;137(4):571–80.
87. Martinez MA. Compounds with Therapeutic Potential against Novel Respiratory 2019 Coronavirus. *Antimicrob Agents Chemother*. 2020 May 1;64(5).
88. Mantlo E, Bukreyeva N, Maruyama J, Paessler S, Huang C. Antiviral activities of type I interferons to SARS-CoV-2 infection. *Antiviral Res*. 2020 Jul 1 8;179:104811.
89. Hellwig K, Geissbuehler Y, Sabidó · Meritxell, Popescu C, Adamo A, Klinger J, et al. Pregnancy outcomes in interferon-beta-exposed patients with multiple sclerosis: results from the European Interferon-beta Pregnancy Registry on behalf of the European Interferon-beta Pregnancy Study Group. *J Neurol*. 123AD;1:3.
90. Hung IFN, Lung KC, Tso EYK, Liu R, Chung TWH, Chu MY, et al. Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. Vol. 395, *The Lancet*. 2020. p. 1695–704.

91. Luo P, Liu Y, Qiu L, Liu X, Liu D, Li J. Tocilizumab treatment in COVID-19: A single center experience. *J Med Virol*. 2020 Jul 1;92(7):814–8.
92. Zhang C, Wu Z, Li JW, Zhao H, Wang GQ. Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality. *Int J Antimicrob Agents*. 2020 May 1 ;55(5).
93. Xu X, Han M, Li T, Sun W, Wang D, Fu B, et al. Effective treatment of severe COVID-19 patients with tocilizumab. *Proc Natl Acad Sci U S A*. 2020;117(20):10970–5.
94. Tabarsi P, Barati S, Jamaati H, Haseli S, Marjani M, Moniri A, et al. Evaluating the effects of Intravenous Immunoglobulin (IVIg) on the management of severe COVID-19 cases: A randomized controlled trial. *Int Immunopharmacol*. 2021 Jan 1;90.
95. Dorland. *Dorland's Illustrated Medical Dictionary*. 32th editi. USA: Elsevier Saunders; 2012.
96. Pirjani R, Hosseini R, Soori T, Rabiei M, Hosseini L, Abiri A, et al. Maternal and neonatal outcomes in COVID-19 infected pregnancies: a prospective cohort study. *J Travel Med*. 2020;2020:1–7.
97. Yang R, Mei H, Zheng T, Fu Q, Zhang Y, Buka S, et al. Pregnant women with COVID-19 and risk of adverse birth outcomes and maternal-fetal vertical transmission: a population-based cohort study in Wuhan, China.
98. Overview | Preterm labour and birth | Guidance | NICE [Internet]. [diakses pada 2022 Apr 18]. Available from: <https://www.nice.org.uk/guidance/ng25>
99. Knight M, Bunch K, Vousden N, Morris E, Simpson N, Gale C, et al. Characteristics and outcomes of pregnant women admitted to hospital with confirmed SARS-CoV-2 infection in UK: national population based cohort study. *BMJ*. 2020 Jun 8;369.
100. Vousden N, Bunch K, Morris E, Simpson N, Gale C, O'Brien P, et al. The incidence, characteristics and outcomes of pregnant women hospitalized with symptomatic and asymptomatic SARS-CoV-2 infection in the UK from March to September 2020: A national cohort study using the UK Obstetric Surveillance System (UKOSS). *PLoS One*. 2021 May 1;16(5):e0251123.
101. Cruz-Lemini M, Perez EF, De La Cruz Conty ML, Aguilar AC, Pardilla MBE, Rodriguez PP, et al. Obstetric Outcomes of SARS-CoV-2 Infection in Asymptomatic Pregnant Women. *Viruses*. 2021 Jan 1 ;13(1).
102. Gurol-Urganci I, Jardine JE, Carroll F, Draycott T, Dunn G, Fremeaux A, et al. Maternal and perinatal outcomes of pregnant women with SARS-CoV-2 infection at the time of birth in England: national cohort study. *Am J Obstet Gynecol*. 2021;225(5):522.e1-522.e11.
103. Nayak MK, Panda SK, Panda SS, Rath S, Ghosh A, Mohakud NK. Neonatal

outcomes of pregnant women with COVID-19 in a developing country setup. *Pediatr Neonatol*. 2021 Sep 1;62(5):499–505.

104. Novita NF, Destianty DP. INTERAKSI OBAT TERHADAP PERPANJANGAN INTERVAL QT. *Farmaka*. 2020 Feb 9;18(1):110–8.
105. T.W.Sadler. *Embriologi Kedokteran Langman*. ED.12. jakarta: Penerbit Buku Kedokteran EGC; 2012.
106. Yuan Z, Zhang LZ, Li B, Chung HT, Jiang JX, Chiang JY, et al. Investigation of echocardiographic characteristics and predictors for persistent defects of patent foramen ovale or patent ductus arteriosus in Chinese newborns. *Biomed J*. 2021 Apr 1 [;44(2):209–16. A
107. Kuno T, Aikawa T, Takagi H, Ishikawa K. Myocardial injury characterized by elevated cardiac troponin and in-hospital mortality of COVID-19: an insight from a meta-analysis. [diakses pada 7 April 2022]; Available from: <http://www.prisma-statement.org>

